Novel evidence for retinoic acid-induced G (Rig-G) as a tumor suppressor by activating p53 signaling pathway in lung cancer.
Rig-G
epithelial-mesenchymal transition
lung adenocarcinoma
metastasis
p53
prognosis
therapy
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
22
01
2020
revised:
20
05
2020
accepted:
23
06
2020
pubmed:
3
8
2020
medline:
11
3
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
Lung cancer is one of most common malignancies worldwide. We have previously identified retinoic acid-induced gene G (Rig-G) as a tumor suppressor in not only acute promyelocytic leukemia, but also in other solid tumors. However, the clinical significance of Rig-G and the underlying mechanism(s) for its biological function in lung cancer remain largely unexplored. Herein, we first compared the expression of Rig-G between lung cancer (n = 138) and normal tissues (n = 23), from public-available data sets and our patient cohort. We further analyzed the correlation of Rig-G expression with key clinico-pathological features and survival outcomes in a multi-site clinical cohort of 300 lung cancer patients. Functional studies for Rig-G were performed in cell lines, and an animal model to support clinical findings. We found that Rig-G was frequently downregulated in lung cancer tissues and cell lines, and correlated with poor prognosis in lung cancer patients. Overexpression of Rig-G led to significantly reduced cell growth and suppressed migration in A549 and NCI-H1944 cells, accompanied by reduced epithelial-mesenchymal transition. Likewise, restoration of Rig-G in Lewis lung carcinoma cells permitted development of fewer cancer metastases versus controls in an animal model. Gene expression profiling results identified p53 pathway as a key downstream target of Rig-G, and p53 inhibition by pifithrin-α caused abrogation of tumor-suppressive effects of Rig-G in lung cancer. In conclusion, we, for the first time, have identified Rig-G as a novel and important tumor suppressor, which may serve as a potential therapeutic target for restoring p53 expression in lung cancer patients.
Identifiants
pubmed: 32741018
doi: 10.1096/fj.201903220R
pmc: PMC7725982
mid: NIHMS1620508
doi:
Substances chimiques
IFIT3 protein, human
0
Intracellular Signaling Peptides and Proteins
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11900-11912Subventions
Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187956
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
EMBO Rep. 2018 Jan 2;19(2):305-319
pubmed: 29295817
Cancer Treat Rev. 2019 Jan;72:15-27
pubmed: 30445271
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
pubmed: 11707567
Mol Biol Cell. 2011 Dec;22(24):4750-64
pubmed: 22031288
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7406-11
pubmed: 9207104
Neoplasia. 2009 Jan;11(1):22-31, 6p following 31
pubmed: 19107228
Cancer Res. 2018 Jan 15;78(2):359-371
pubmed: 29187402
Oncogene. 2008 Sep 18;27(42):5543-53
pubmed: 18504427
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Genomics. 1998 Dec 1;54(2):267-77
pubmed: 9828129
J Thorac Oncol. 2009 Jun;4(6):679-83
pubmed: 19461401
Cancer Res. 2004 Apr 1;64(7):2439-48
pubmed: 15059897
Cancer Res. 2009 Apr 15;69(8):3673-80
pubmed: 19351818
Biomed Res Int. 2015;2015:621324
pubmed: 26064932
Mutat Res. 2017 Jul;773:1-13
pubmed: 28927521
Biochem Biophys Res Commun. 2013 Mar 15;432(3):425-30
pubmed: 23415865
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Transl Lung Cancer Res. 2018 Feb;7(1):4-20
pubmed: 29535909
J Clin Med. 2016 Jan 27;5(2):
pubmed: 26828526
Oncotarget. 2016 Oct 4;7(40):66032-66050
pubmed: 27602766
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16448-53
pubmed: 17050680
Breast Cancer. 2018 Sep;25(5):529-538
pubmed: 29516369
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593